COMP <GO>
PTGX vs SYRE // PIOTROSKI F-SCORE QUALITY
Protagonist Therapeutics Inc. (NASDAQ) VS. Spyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PTGX 4
— SYRE 4
▲ PIOTROSKI F-SCORE QUALITY LEADER: PTGX
LAST: $144.34 (+1.55%) • MKT CAP: $9.34B
piotroski-score
6/9
LAST: $98.96 (-0.79%) • MKT CAP: $10.33B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. SYRE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | SYRE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | -20.00% | +3.30 | PTGX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.60% | -1.64% | +2.24 | PTGX | /fcf-yield <GO> |
| Operating Margin | -6.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -5.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 17.60% | -17.60 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 6/9 | 5/9 | +1.00 | PTGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.8 | 61.9 | -5.10 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.89 | +0.10 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 22.0x | +9.00 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.34B | $10.33B | -$992.9M | SYRE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | SYRE REV | PTGX GROSS % | SYRE GROSS % | PTGX FCF | SYRE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | $56.1M | -$169.3M |
| FY 2024 | $0 | $0 | — | — | $182.8M | -$157.4M |
| FY 2023 | $0 | $886.0K | — | — | -$70.2M | -$99.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
SYRE // BETA 0.89